Controlled Substances

This fact sheet provides updated information (as of April 2025) on the issue of drug diversion in health care settings. Drug diversion is defined as any criminal act or deviation that removes a prescription drug from its intended path from the manufacturer to the patient, and while the act of diversion can occur in a variety of settings and be committed by anyone, it is particularly likely to occur in healthcare settings by healthcare workers due to the ease in which they can access prescription drugs. Drug diversion in health care is a serious issue that can result in patient harm, financial loss to the healthcare entity, and civil and criminal litigation based on the perpetrator’s actions....

Kratom is an herb derived from a leafy Southeast Asian tree and contains two psychoactive compounds that can bind to opioid receptors in the brain and produce a pharmacological response similar to effects produced by other opioid agonists, such as morphine. As of April 2025, 24 states and the District of Columbia regulate kratom. This document: (1) provides a singular resource for each jurisdiction’s laws; (2) allows for a comparison of these laws between jurisdictions; and (3) identifies and highlights interesting provisions. ...

Syringe services programs (SSP) are harm reduction programs that provide a wide range of services including, but not typically limited to, the provision of new, unused hypodermic needles and syringes and other injection drug use supplies, such as cookers, tourniquets, alcohol wipes, and sharps waste disposal containers, to people who inject drugs. In this summary, readers will find information with respect to SSPs for each state, including citations to applicable statutes and/or regulations, whether the state allows SSPs by statute, whether there are any municipal or county ordinances or regulations in place within the state, program components, miscellaneous provisions, and information on any pending legislation....

In this survey, the Legislative Analysis and Public Policy Association (LAPPA) examines the legislative and regulatory response at the state level to the issue of fentanyl cleanup. As at the federal level, there is little policy in this area, and the only exceptions to that rule are very recent. Findings are presented jurisdiction by jurisdiction for easy comparison among the states, and include pending legislation....

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) details the effects of the substance ibogaine in humans, discusses its regulation on the state and federal level, and highlights research being conducted relative to renewed interest in the substance....

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) details how opioid settlement proceeds are being disbursed to state and local governments, how those governments are choosing to spend those funds, and the obstacles that can prevent these funds from helping those who have been affected by the opioid epidemic....

In this fact sheet the Legislative Analysis and Public Policy Association (LAPPA) provides an overview of the sudden increase in the presence of BTMPS in the illicit drug supply and its rapid proliferation across the country, which has left drug policy experts and harm reduction specialists puzzled as to why it is in the supply and how it will affect the individuals consuming it....

In an effort to save lives, states have implemented laws to make it easier for first responders and the general public to obtain overdose reversal agents, such as naloxone. Additionally, to encourage people to assist an individual who is or may be suffering an overdose, the majority of states also enacted laws which protect laypeople who administer overdose reversal agents, in good faith, in an emergency from civil and/or criminal liability. The Legislative Analysis and Public Policy Association (LAPPA) undertook an extensive research project to determine the current status of overdose reversal agent access laws throughout the United States, including the District of Columbia and all U.S. territories. As of January 2025, all 50 states and the District of Columbia have some form of an overdose reversal agent access law....